Baidu
map

Brit J Cancer:利用手机通过全民科学对膀胱癌免疫组化生物标记的筛选研究

2018-07-21 AlexYang MedSci原创

免疫组化(IHC)治疗通常在个性化癌症治疗中使用。相关专家利用大数据分析来发现预测性的生物标记将非常耗时。最近,有研究人员调查了将大众外包作为一种方法来分析免疫染色癌症样本,从而发现能够预测癌症生存的生物标记。研究人员通过一个手机端app "Reverse the Odds"来对膀胱癌TMA核心样本进行大众分析。研究人员将从公众获得的评分进行了混样分析,并且与由专家设定的黄金标准评分进行了比较,他

免疫组化(IHC)治疗通常在个性化癌症治疗中使用。相关专家利用大数据分析来发现预测性的生物标记将非常耗时。最近,有研究人员调查了将大众外包作为一种方法来分析免疫染色癌症样本,从而发现能够预测癌症生存的生物标记。

研究人员通过一个手机端app "Reverse the Odds"来对膀胱癌TMA核心样本进行大众分析。研究人员将从公众获得的评分进行了混样分析,并且与由专家设定的黄金标准评分进行了比较,他们还利用大众评分来评估了与疾病特异性生存的相关性。研究数据总共收集了721天,总共有4744339次鉴定。每次鉴定平均时间花费为15秒,其贡献的非游戏时间大约为20000小时。研究发现,通过标记测试进行的大众分析与专家H-评分(染色强度*比例)之间的相关性在0.65到0.92之间,10个相关系数中的6个至少为0.80。另外,至少有2个生物标记(MRE11和CK20)与膀胱癌患者的生存显著相关,且有3个标记的结果显示值得专家进一步跟进。

最后,研究人员指出,通过移动手机app进行的大众分析具有精准筛选IHC数据的能力,并且能够极大的加快发现生物标记的速度。

原始出处:

Peter Smittenaar, Alexandra K. Walker, Shaun McGill et al. Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer. Brit J Cancer. 11 July 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1345374, encodeId=347513453e490, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438903, encodeId=b190143890304, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584404, encodeId=f61f1584404f3, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333151, encodeId=446433315150, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Jul 21 12:25:26 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333144, encodeId=83c833314473, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 21 11:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1345374, encodeId=347513453e490, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438903, encodeId=b190143890304, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584404, encodeId=f61f1584404f3, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333151, encodeId=446433315150, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Jul 21 12:25:26 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333144, encodeId=83c833314473, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 21 11:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1345374, encodeId=347513453e490, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438903, encodeId=b190143890304, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584404, encodeId=f61f1584404f3, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333151, encodeId=446433315150, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Jul 21 12:25:26 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333144, encodeId=83c833314473, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 21 11:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1345374, encodeId=347513453e490, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438903, encodeId=b190143890304, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584404, encodeId=f61f1584404f3, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333151, encodeId=446433315150, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Jul 21 12:25:26 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333144, encodeId=83c833314473, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 21 11:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-21 183****7028

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1345374, encodeId=347513453e490, content=<a href='/topic/show?id=8907693e0fa' target=_blank style='color:#2F92EE;'>#生物标记#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69370, encryptionId=8907693e0fa, topicName=生物标记)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=278f2500221, createdName=12498fa0m11暂无昵称, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438903, encodeId=b190143890304, content=<a href='/topic/show?id=eb522911994' target=_blank style='color:#2F92EE;'>#免疫组化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29119, encryptionId=eb522911994, topicName=免疫组化)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584404, encodeId=f61f1584404f3, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Mon Jul 23 02:26:00 CST 2018, time=2018-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333151, encodeId=446433315150, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Sat Jul 21 12:25:26 CST 2018, time=2018-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333144, encodeId=83c833314473, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sat Jul 21 11:50:00 CST 2018, time=2018-07-21, status=1, ipAttribution=)]
    2018-07-21 医者仁心5538

    学习了

    0

相关资讯

Oncogene:基因组算法立功!发现膀胱癌新靶点

纽约西奈山卫生系统(Mount Sinai Health System in New York)的研究者通过算法模型,确定了两种生物标志物,它们有可能帮助肿瘤学家预测 p53 样膀胱癌患者的预后,并对其进行针对性治疗。相关论文发表在近期的《Oncogene》上。

Sci Rep:通过尿液代谢组学分析对膀胱癌复发的监控研究

非肌肉侵入性膀胱癌(NMIBC)是世界范围上最为常见的的恶性肿瘤之一。NMIBC主要通过膀胱肿瘤的通过尿道的切除(TURBT)和膀胱内疗法进行治疗,并且在实体瘤中具有最高的复发率。因此,需要基于重复的膀胱镜检查和尿细胞学检查进行终生的监控,但是上述两种方法均具有缺陷,包括了敏感性和特异性的缺乏,侵入性和护理费用。最近,有研究人员进行了一个调查性的临床研究来检查NMBIC患者在TURBT前后以及在随

Sci Rep:在肌肉侵入性膀胱癌中,膀胱部分切除术后的肿瘤结果、生活质量结果和并发症结果研究

最近,有研究人员为了评估患有肌肉侵入性膀胱癌(MIBC)患者经历膀胱部分切除术(PC)后的肿瘤结果、相关的并发症和术后健康相关的生活质量(HR-QoL),他们进行了相关的研究,研究包括了27名经历了cT2 MIBC开放PC手术的患者。研究人员利用一个简单的Cox's比例风险回归模型来评估一些潜在的预后因素与生存的关系,利用EORTC QLQ-C30调查问卷3.0版本评估了术后HR-QoL。研究发现

Lab Invest:Fezf2功能的丧失能够促进膀胱癌恶性发展

前脑胚胎锌指蛋白2(Fezf2)是一个进化保守的锌指结构转录抑制子。之前报道它是一个肿瘤抑制因子;然而,Fezf2在膀胱癌中的作用或者相关的机制还没有很好的研究。最近,有研究人员展示了与临近的非肿瘤组织和正常泌尿道上皮细胞相比,Fezf2的表达在膀胱癌组织和细胞系中下调。研究人员同样在196名膀胱癌患者中,回顾性的分析了Fezf2与各种临床病理特性的相关性。研究发现Fezf2的低表达量与更大的肿瘤

Oncogene:microR-106b被鉴定为是类p53膀胱癌的一种预后生物标记

膀胱癌可根据基因表达模式可以分为不同的亚型。类P53肌肉侵入型膀胱癌通常对基于铂的化疗具有抗性,并且展现了异质性的临床结果,且处于管腔亚型和基础亚型之间。对该亚型膀胱癌最优的治疗方法、能更好的对该类型肿瘤进行风险分层的方法以及新的治疗靶标的鉴定都是迫切需要解决的。MicroRNAs(miRNAs)在癌症的发生和肿瘤恶化过程中具有重要的作用。在过去的几年中,miRNA表达特征在不同类型的肿瘤中(包括

NCCN临床实践指南:膀胱癌(2018.V5)

2018年7月,美国国家综合癌症网络(NCCN)发布了膀胱癌指南2018年第5版,指南主要内容包括: 指南更新摘要 膀胱癌 临床表现和初始评估 非侵袭性或Tis,初步评估/手术治疗 肌层侵袭或转移,初步评估/手术治疗,额外检查 膀胱/移行细胞癌影像学检查 手术治疗原则 病理检查原则 非肌层浸润性膀胱癌复发概率 膀胱癌:非肌层以及移行细胞变异组织学 术后随访 膀胱灌注治疗原则 化疗原则 侵袭性疾病放

Baidu
map
Baidu
map
Baidu
map